JP2015522526A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522526A5 JP2015522526A5 JP2015510590A JP2015510590A JP2015522526A5 JP 2015522526 A5 JP2015522526 A5 JP 2015522526A5 JP 2015510590 A JP2015510590 A JP 2015510590A JP 2015510590 A JP2015510590 A JP 2015510590A JP 2015522526 A5 JP2015522526 A5 JP 2015522526A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- antibody construct
- construct
- monovalent antibody
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 48
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 48
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 48
- 239000000427 antigen Substances 0.000 claims description 25
- 102000036639 antigens Human genes 0.000 claims description 25
- 108091007433 antigens Proteins 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 14
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 14
- 239000000833 heterodimer Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 238000002844 melting Methods 0.000 claims description 8
- 230000008018 melting Effects 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 229960002087 pertuzumab Drugs 0.000 claims description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 229960000575 trastuzumab Drugs 0.000 claims description 3
- 102000009490 IgG Receptors Human genes 0.000 claims description 2
- 108010073807 IgG Receptors Proteins 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 210000004962 mammalian cell Anatomy 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 2
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims 2
- 101100402572 Arabidopsis thaliana MS5 gene Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000015694 estrogen receptors Human genes 0.000 claims 1
- 108010038795 estrogen receptors Proteins 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 229960003387 progesterone Drugs 0.000 claims 1
- 239000000186 progesterone Substances 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 description 22
- 230000035772 mutation Effects 0.000 description 14
- 229940022353 herceptin Drugs 0.000 description 5
- 230000009824 affinity maturation Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261645547P | 2012-05-10 | 2012-05-10 | |
| US61/645,547 | 2012-05-10 | ||
| US201261671640P | 2012-07-13 | 2012-07-13 | |
| US61/671,640 | 2012-07-13 | ||
| US201261722070P | 2012-11-02 | 2012-11-02 | |
| US61/722,070 | 2012-11-02 | ||
| US201361762812P | 2013-02-08 | 2013-02-08 | |
| US61/762,812 | 2013-02-08 | ||
| PCT/CA2013/050358 WO2013166604A1 (en) | 2012-05-10 | 2013-05-08 | Single-arm monovalent antibody constructs and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015522526A JP2015522526A (ja) | 2015-08-06 |
| JP2015522526A5 true JP2015522526A5 (enExample) | 2017-11-02 |
| JP6849868B2 JP6849868B2 (ja) | 2021-03-31 |
Family
ID=49550028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510590A Expired - Fee Related JP6849868B2 (ja) | 2012-05-10 | 2013-05-08 | シングルアーム一価抗体構築物およびその用途 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20150125449A1 (enExample) |
| EP (1) | EP2847224A4 (enExample) |
| JP (1) | JP6849868B2 (enExample) |
| KR (1) | KR20150008171A (enExample) |
| CN (1) | CN104520327B (enExample) |
| AU (1) | AU2013258844B2 (enExample) |
| CA (1) | CA2873720A1 (enExample) |
| RU (1) | RU2014148704A (enExample) |
| WO (1) | WO2013166604A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9562109B2 (en) | 2010-11-05 | 2017-02-07 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| CA2828811C (en) | 2011-03-03 | 2021-09-21 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
| EP2773671B1 (en) | 2011-11-04 | 2021-09-15 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| WO2014067011A1 (en) * | 2012-11-02 | 2014-05-08 | Zymeworks Inc. | Crystal structures of heterodimeric fc domains |
| KR20140135233A (ko) | 2012-03-14 | 2014-11-25 | 리제너론 파마슈티칼스 인코포레이티드 | 다중특이성 항원-결합 분자 및 그것의 용도 |
| US9499634B2 (en) | 2012-06-25 | 2016-11-22 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
| JP6498601B2 (ja) | 2012-07-13 | 2019-04-10 | ザイムワークス，インコーポレイテッド | 多価ヘテロ多量体足場設計および構築物 |
| US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
| BR112016000106B1 (pt) | 2013-07-09 | 2023-11-21 | Annexon, Inc. | Anticorpos anti-c1q e usos dos mesmos, célula de hibridoma, composição farmacêutica e métodos de detecção de sinapses em uma amostra biológica referências cruzadas a pedidos relacionados |
| KR20160083949A (ko) * | 2013-11-13 | 2016-07-12 | 자임워크스 인코포레이티드 | Egfr 및/또는 her2를 표적화하는 1가 항원 결합 작제물 및 이의 용도 |
| CN105980409B (zh) * | 2013-11-27 | 2023-07-18 | 酵活生物制药有限公司 | 靶向her2的双特异性抗原结合构建体 |
| DK3223848T3 (da) | 2014-11-27 | 2025-03-03 | Zymeworks Bc Inc | Fremgangsmåder til anvendelse af bispecifikke antigenbindingskonstrukter målrettet her2 |
| US10336816B2 (en) * | 2015-02-24 | 2019-07-02 | Academia Sinica | Phage-displayed single-chain variable fragment library |
| EP3294772B1 (en) * | 2015-05-13 | 2025-11-05 | Zymeworks BC Inc. | Antigen-binding constructs targeting her2 |
| MY189159A (en) | 2015-07-06 | 2022-01-29 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| CA2991799A1 (en) | 2015-07-15 | 2017-01-19 | Zymeworks Inc. | Drug-conjugated bi-specific antigen-binding constructs |
| EP3337826A1 (en) | 2015-08-20 | 2018-06-27 | Sutro Biopharma, Inc. | Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies |
| IL296130A (en) | 2015-11-24 | 2022-11-01 | Annexon Inc | Anti-complement factor c1q fab fragments and their uses |
| CN109153727A (zh) * | 2016-04-15 | 2019-01-04 | 酵活有限公司 | 靶向免疫治疗剂的多特异性抗原结合构建体 |
| US11352446B2 (en) | 2016-04-28 | 2022-06-07 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| WO2018156785A1 (en) * | 2017-02-22 | 2018-08-30 | Sutro Biopharma, Inc. | Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same |
| JOP20190222A1 (ar) | 2017-04-11 | 2019-09-24 | Zymeworks Inc | الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3 |
| AR112603A1 (es) | 2017-07-10 | 2019-11-20 | Lilly Co Eli | Anticuerpos biespecíficos inhibidores de punto de control |
| AU2018380979B2 (en) | 2017-12-08 | 2023-07-20 | argenx BV | Use of FcRn antagonists for treatment of generalized myasthenia gravis |
| AU2019262953B2 (en) | 2018-04-30 | 2025-12-04 | Regeneron Pharmaceuticals, Inc. | Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof |
| SG11202011849VA (en) | 2018-06-08 | 2020-12-30 | Argenx Bvba | Compositions and methods for treating immune thrombocytopenia |
| CN112771379B (zh) | 2018-08-17 | 2024-07-02 | 瑞泽恩制药公司 | 用于测定多聚体蛋白质的量和纯度的方法和色谱系统 |
| EP4087875B1 (en) | 2020-01-08 | 2024-08-28 | Argenx BV | Antagonists of human neonatal fc receptor (fcrn) for treating pemphigus disorders |
| US20240383998A1 (en) * | 2021-04-20 | 2024-11-21 | Korea University Research And Business Foundation | Asymmetric antibody with improved cytotoxicity against cancer cells |
| WO2023114763A1 (en) * | 2021-12-13 | 2023-06-22 | Annexon, Inc. | Anti-complement factor c1q antibodies with single binding arms and uses thereof |
| JP2025518971A (ja) * | 2022-06-15 | 2025-06-19 | アルジェニクス ビーブイ | ｐＨ依存性ＨＳＡ結合分子及び使用方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002332087A1 (en) * | 2002-10-08 | 2004-05-04 | Immunomedics, Inc. | Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents |
| ES2384569T3 (es) * | 2003-12-19 | 2012-07-09 | Genentech, Inc. | Fragmentos de anticuerpos monovalentes útiles como agentes terapéuticos |
| GB0614780D0 (en) * | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| CA2682605A1 (en) * | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| PL2235064T3 (pl) * | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
| JP2011513432A (ja) * | 2008-03-06 | 2011-04-28 | ジェネンテック， インコーポレイテッド | ｃ−ｍｅｔ及びＨＥＲアンタゴニストの併用療法 |
| CA2739302A1 (en) * | 2008-10-17 | 2010-04-22 | Brendan C. Bender | Treatment method |
| EP3208281A1 (en) * | 2010-03-29 | 2017-08-23 | Zymeworks, Inc. | Antibodies with enhanced or suppressed effector function |
| EP4477668A3 (en) * | 2010-04-20 | 2025-03-19 | Genmab A/S | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| EP2575880B1 (en) * | 2010-05-27 | 2019-01-16 | Genmab A/S | Monoclonal antibodies against her2 epitope |
| CA2804280A1 (en) * | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Chimeric clotting factors |
| US9562109B2 (en) * | 2010-11-05 | 2017-02-07 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| US9738724B2 (en) * | 2012-06-08 | 2017-08-22 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| EP3068430A4 (en) * | 2013-11-13 | 2017-07-05 | Zymeworks Inc. | Methods using monovalent antigen binding constructs targeting her2 |
| JP6531010B2 (ja) * | 2015-08-19 | 2019-06-12 | 本田技研工業株式会社 | 駆動装置、輸送機器及び蓄電器制御方法 |
-
2013
- 2013-05-08 JP JP2015510590A patent/JP6849868B2/ja not_active Expired - Fee Related
- 2013-05-08 RU RU2014148704A patent/RU2014148704A/ru not_active Application Discontinuation
- 2013-05-08 AU AU2013258844A patent/AU2013258844B2/en not_active Ceased
- 2013-05-08 WO PCT/CA2013/050358 patent/WO2013166604A1/en not_active Ceased
- 2013-05-08 CA CA2873720A patent/CA2873720A1/en not_active Abandoned
- 2013-05-08 US US14/399,789 patent/US20150125449A1/en not_active Abandoned
- 2013-05-08 CN CN201380036769.2A patent/CN104520327B/zh not_active Expired - Fee Related
- 2013-05-08 EP EP13788508.3A patent/EP2847224A4/en not_active Withdrawn
- 2013-05-08 KR KR1020147034415A patent/KR20150008171A/ko not_active Ceased
-
2016
- 2016-10-20 US US15/298,625 patent/US20170174783A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522526A5 (enExample) | ||
| Ko et al. | An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies | |
| JP6328087B2 (ja) | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 | |
| Zhang et al. | Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics | |
| JP6185584B2 (ja) | 電荷の斥力相互作用を使用することによりホモダイマータンパク質の混合物を調製するための方法 | |
| Schlothauer et al. | Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies | |
| JP2019031529A5 (enExample) | ||
| US20170247474A1 (en) | Multivalent antigen-binding proteins | |
| CN102448987B (zh) | 一种抗vegf的单克隆抗体及含有该抗体的药物组合物 | |
| US20210054049A1 (en) | Variant domains for multimerizing proteins and separation thereof | |
| ES2667003T3 (es) | Anticuerpos para receptores P2X7 oligoméricos no funcionales | |
| RU2014148704A (ru) | Конструкции одноруких моновалентных антител и их использование | |
| WO2017101828A1 (zh) | 基于ch3结构域的异二聚体分子、其制备方法及用途 | |
| JP2015528003A5 (enExample) | ||
| JP2016190844A (ja) | 単量体抗体Ｆｃ | |
| KR20170044613A (ko) | 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도 | |
| BR112019025468A2 (pt) | Complexo proteico, cadeia de aminoácidos, ácido nucleico, vetor, método para definir a sequência de aminoácidos, método para produzir a cadeia de aminoácidos e complexo proteico | |
| US20240092899A1 (en) | Bispecific antibody | |
| WO2019023097A1 (en) | ASYMMETRIC BISPECIFIC ANTIBODIES AND THEIR USE | |
| Zhao et al. | A new approach to produce IgG4-like bispecific antibodies | |
| JPWO2022166728A5 (enExample) | ||
| JP2025528101A (ja) | 多重特異性ポリペプチド複合体 | |
| JP2025528087A (ja) | 二量体化可能な腫瘍抗原及び免疫刺激抗原を標的とする多重特異性抗体 |